Atara Biotherapeutics, Inc. (ATRA)

Market Cap	180.97M
Revenue (ttm)	6.86M
Net Income (ttm)	-304.54M
Shares Out	101.10M
EPS (ttm)	-2.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27
Open	1.80
Previous Close	1.78
Day's Range	1.73 - 1.86
52-Week Range	1.25 - 5.64
Beta	1.03
Analysts	Strong Buy
Price Target	21.73 (+1,113.97%)
Earnings Date	Nov 7, 2023

About ATRA

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2014
• Employees: 317
• Stock Exchange: NASDAQ
• Ticker Symbol: ATRA

Financial Performance

In 2022, ATRA's revenue was $63.57 million, an increase of 212.55% compared to the previous year's $20.34 million. Losses were -$228.30 million, -32.88% less than in 2021.

Analyst Forecast

According to 6 analysts, the average rating for ATRA stock is "Strong Buy." The 12-month stock price forecast is $21.73, which is an increase of 1,113.97% from the latest price.

Price Target

$21.73

(1,113.97% upside)

Analyst Consensus: Strong Buy